CoverageKuopio, Finland
Kuopio Health presents Rayca Precision: building a collective memory for drug discovery
A Kuopio Health member feature on how Rayca turns the lessons of past programmes, including what failed, into molecular intelligence for the next one.

Kuopio Health has published a feature on Rayca Precision, “Building a collective memory for drug discovery”, in its series presenting Kuopio Health members. Written by Marja-Terttu Nyman-Lappalainen from a conversation with Pouya Behrouzi, Co-founder and CEO, it covers how Rayca is rethinking computational drug discovery, why human expertise remains essential in the age of AI, and what makes Kuopio and Finland a strong environment for the work.
“Drug development needs a memory of what failed, and why. That is what we are building.”
When failure becomes knowledge
The article starts from a contradiction. AI models can now predict protein structures, generate molecules and help explore biological mechanisms, yet developing a new medicine remains long, expensive and failure-prone. Inside large R&D organisations, what each programme learns, including why a candidate failed, is scattered across projects, teams and computational systems. Rayca’s aim is to turn those lessons into institutional molecular intelligence that keeps informing design after a programme has ended.
More than another AI model
Rayca is not building one more standalone model. Its platform brings hundreds of models and simulation engines together, ready to run, and connects them with experiments and an organisation’s own data and knowledge. It is deployed inside the company’s own secured research environment, so proprietary evidence, models and programme knowledge stay under its control.
“We are not trying to win by building one more model. We build the molecular intelligence that connects models, simulation, experiments and a company’s own evidence, so every programme learns from the ones before it.”
Scientists steer the science
The feature follows a programme from a biological hypothesis to a better molecule: modelling and simulating the target, generating candidates across small molecules, peptides, antibodies, nanobodies, inhibitors and degraders, and checking developability liabilities such as toxicity, immunogenicity, stability, formulation, delivery and manufacturability before laboratory work begins. Results from partner laboratories feed the next design cycle. AI agents automate much of the computational work, while scientists review the methods and evidence at decision gates, and every design can be traced to the evidence and reasoning behind it.
It also describes Rayca’s co-development model, with partner laboratories connected directly into the design cycle: the HPV-driven cancer programme with the University of Arkansas for Medical Sciences and the University of New Mexico, and the partnerships with QurieGen and Data Powered Therapeutics.
Why Kuopio and Finland
Through the Kuopio Health network and the wider Finnish life-science ecosystem, Rayca wants to connect with computational and machine-learning teams, pharmaceutical companies, biotech teams with a difficult molecular programme, translational researchers and early-stage therapeutic companies.
“The research in Kuopio is outstanding. The level of expertise in computer-aided drug design is really at the edge of science.”
The full article is on the Kuopio Health website.

